Boston-based MPM Bioimpact sold 313,571 shares of MoonLake Immunotherapeutics in the third quarter, reducing the position by about $14.8 million. The move marked a full exit for MPM, which reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback